Insider Deck research · News

URGN stock news · UroGen Pharma Ltd.

Latest UroGen Pharma Ltd. (URGN) stock news, headlines, and research context on Insider Deck. Sector: Healthcare. Industry: Biotechnology. Market cap $2.3B.

News desk

UroGen Pharma Ltd. wire

Read the briefing on Insider Deck — headline, teaser, and desk context stay here. Publisher sites remain optional for the full longform.

7 on the wireUpdated within the hour

MT Newswires·Wed, Aug 5, 4:44 PM

TD Cowen Adjusts UroGen Pharma Price Target to $60 From $50, Maintains Buy Rating

UroGen Pharma (URGN) has an average rating of buy and mean price target of $41.62, according to anal

Insider Deck desk note

Last$46.43
Day+16.31%
SymbolURGN

Cross-check the tape against filings and ownership — the headline is the spark; the desk is the research.

Company KPIsShareholdersBuys vs Sells
Continue on MT Newswires

Frequently asked questions

What is the latest news on URGN?

The URGN news desk aggregates recent headlines with research context for UroGen Pharma Ltd. (Healthcare).

Where can I research URGN on Insider Deck?

UroGen Pharma Ltd. (URGN) research covers KPIs, earnings, fundamentals, institutional ownership, 13F flow, news, and DCF valuation.